# Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

> **NCT00085397** · PHASE2 · UNKNOWN · sponsor: **Dana-Farber Cancer Institute** · enrollment: 40 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** autologous dendritic cell-tumor fusion vaccine
- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** therapeutic autologous dendritic cells

## Key facts

- **NCT ID:** NCT00085397
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2009-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00085397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00085397, "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00085397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*